FULCFulcrum Therapeutics
About Fulcrum Therapeutics
Fulcrum Therapeutics (NASDAQ:FULC) focuses on developing transformative medicines to improve the lives of patients with genetically defined rare diseases. Dedicated to tackling conditions that have limited treatment options, the company leverages advanced scientific research to identify and address the root causes of these diseases. Their pipeline includes projects targeting sickle cell disease and facioscapulohumeral muscular dystrophy, among others. With a steadfast commitment, Fulcrum aims to deliver groundbreaking therapies that can offer renewed hope and tangible benefits to those they serve.
What is FULC known for?
Snapshot
Public US
Ownership
2015
Year founded
90
Employees
Cambridge, United States
Head office
1 of 1
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Newton, US
Products and/or services of Fulcrum Therapeutics
- Losmapimod, aimed at treating Facioscapulohumeral Muscular Dystrophy (FSHD), a progressive and debilitating muscle disorder, by reducing inflammation and muscle degeneration.
- ReDUX4, a Phase 2b trial drug to slow or halt the progression of FSHD by targeting the root genetic cause of the disease.
- FulcrumSeek, a proprietary product engine designed to identify drug targets by integrating genetic and phenotypic insights to accelerate therapeutics.'
- Fulcrum's partnership on discovering therapies for sickle cell disease using small molecule approaches to modulate gene expression.
- Development of therapies for beta-thalassemia, utilizing gene regulation mechanisms to increase hemoglobin production.
- Collaboration on advanced therapy projects leveraging CRISPR technology for precise gene editing in genetic disorders.
Fulcrum Therapeutics executive team
- Mr. Alexander C. SapirCEO, President & Director
- Mr. Alan A. Musso C.M.A., CPAChief Financial Officer
- Mr. Curtis G. Oltmans J.D.Senior VP, Chief Legal Officer & Corporate Secretary
- Dr. Bradley E. Bernstein M.D., Ph.D.Founder
- Dr. Michael R. GreenFounder
- Dr. Rudolf Jaenisch M.D., Ph.D.Founder
- Dr. Tsun-Huei Lee M.D., Ph.D.Founder
- Dr. Danny ReinbergFounder
- Mr. Gregory TourangeauController & Principal Accounting Officer
- Dr. Jeffrey W. Jacobs Ph.D.Chief Scientific Officer